This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Nelipepimut-S
- DrugBank Accession Number
- DB06226
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Nelipepimut S
- Nelipepimut-S
- External IDs
- E-75 PEPTIDE
- E75
- E75 PEPTIDE
Pharmacology
- Indication
Investigated for use/treatment in prostate cancer and breast cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]
Target Actions Organism UHLA class I histocompatibility antigen, A-2 alpha chain Not Available Humans UHLA class I histocompatibility antigen, A-3 alpha chain Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- NeuVax (Apthera, Inc.)
Categories
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antigens
- Antigens, Surface
- Biological Factors
- Biomarkers
- Biomarkers, Tumor
- Cancer Vaccines
- Enzymes
- Enzymes and Coenzymes
- Histocompatibility Antigens
- Intracellular Signaling Peptides and Proteins
- Isoantigens
- Membrane Proteins
- Minor Histocompatibility Antigens
- Neoplasm Proteins
- Oncogene Proteins
- Peptides
- Phosphotransferases
- Phosphotransferases (Alcohol Group Acceptor)
- Protein Kinases
- Protein-Tyrosine Kinases
- Proteins
- Proto-Oncogene Proteins
- Receptor Protein-Tyrosine Kinases
- Receptor, Epidermal Growth Factor
- Receptors, Growth Factor
- Receptors, Peptide
- Transferases
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7M0A29CD8B
- CAS number
- 160212-35-1
References
- General References
- Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448. [Article]
- Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE: Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17. [Article]
- External Links
- Wikipedia
- E75
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Breast Cancer With Low to Intermediate HER2 Expression 1 2 Completed Prevention Breast Cancer 2 2 Completed Prevention Ductal Breast Carcinoma In Situ 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. HLA class I histocompatibility antigen, A-2 alpha chain
Unknown
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Tap binding
- Specific Function
- Involved in the presentation of foreign antigens to the immune system.
- Gene Name
- HLA-A
- Uniprot ID
- P04439
- Uniprot Name
- HLA class I histocompatibility antigen, A-3 alpha chain
- Molecular Weight
- 40840.41 Da
Drug created at March 19, 2008 16:18 / Updated at February 21, 2021 18:52